using molecular replacement to exploit multiple crystal forms

38
Using molecular replacement to exploit multiple crystal forms Randy Read, Airlie McCoy & Gábor Bunkóczi Tom Terwilliger

Upload: zaza

Post on 22-Feb-2016

33 views

Category:

Documents


0 download

DESCRIPTION

Using molecular replacement to exploit multiple crystal forms. Randy Read, Airlie McCoy & Gábor Bunkóczi Tom Terwilliger. Solving the structure of angiotensinogen. Human: 1 crystal form 3.3Å, 1 copy, P4 1 2 1 2 Rat: 2 crystal forms 2.8Å, 2 copies, C2 3.15Å, 2 copies, P3 2 21 - PowerPoint PPT Presentation

TRANSCRIPT

Page 1: Using molecular replacement to  exploit multiple crystal forms

Using molecular replacement to exploit multiple crystal forms

Randy Read, Airlie McCoy & Gábor Bunkóczi Tom Terwilliger

Page 2: Using molecular replacement to  exploit multiple crystal forms

Solving the structure of angiotensinogen• Human: 1 crystal form

• 3.3Å, 1 copy, P41212• Rat: 2 crystal forms

• 2.8Å, 2 copies, C2• 3.15Å, 2 copies, P3221

• Mouse: 2 crystal forms• 2.1Å, 1 copy, P6122• 2.95Å, 4 copies, C2221

Page 3: Using molecular replacement to  exploit multiple crystal forms

Human angiotensinogen: molecular replacement

human

Page 4: Using molecular replacement to  exploit multiple crystal forms

Human angiotensinogen: molecular replacement

human

Page 5: Using molecular replacement to  exploit multiple crystal forms

Human angiotensinogen: molecular replacement

human

Page 6: Using molecular replacement to  exploit multiple crystal forms

Human angiotensinogen after MR

Final modelMR model

map CC = 0.38

Page 7: Using molecular replacement to  exploit multiple crystal forms

Human angiotensinogen after MR+DM

Final modelMR model

map CC = 0.50

Page 8: Using molecular replacement to  exploit multiple crystal forms

Solving angiotensinogen structures

human

rat C2

rat P3221

+ GdCl3

Page 9: Using molecular replacement to  exploit multiple crystal forms

Rat C2 angiotensinogen after MR with density + 2-fold averaging

Final modelMR model

map CC = 0.44(0.48 with GdCl3)

Page 10: Using molecular replacement to  exploit multiple crystal forms

Rat C2 angiotensinogen after 4-fold multicrystal averaging

Final modelMR model

map CC = 0.53(0.59 with GdCl3)

Page 11: Using molecular replacement to  exploit multiple crystal forms

S-S (18-138)

S-S (18-138)

Renin

Renin:angiotensinogen complex

Page 12: Using molecular replacement to  exploit multiple crystal forms
Page 13: Using molecular replacement to  exploit multiple crystal forms
Page 14: Using molecular replacement to  exploit multiple crystal forms

Solving Drosophila GST2 (1M0U)• Difficult structure from Bogos Agianian

(Piet Gros)• Find one of two copies with ensemble of 3

structures (28-30% identity)• search for second copy fails

• Find second copy as density from first• this succeeds: TFZ=10.0• trick to doing this: assign low error to first

copy, higher error to second

Page 15: Using molecular replacement to  exploit multiple crystal forms

How does averaging add information?• Nyquist-Shannon sampling theorem:

• doubly-sampled Fourier transform can be reconstructed perfectly

Page 16: Using molecular replacement to  exploit multiple crystal forms

Molecule and molecular transform

(Images courtesy of Kevin Cowtan)

Page 17: Using molecular replacement to  exploit multiple crystal forms

Crystal diffraction samples molecular transform on reciprocal lattice

(Images courtesy of Kevin Cowtan)

Page 18: Using molecular replacement to  exploit multiple crystal forms

Non-isomorphism changes sampling of molecular transform

(Images courtesy of Kevin Cowtan)

Cell change

Rotated molecule

Page 19: Using molecular replacement to  exploit multiple crystal forms

Absolute vs. relative cell change

b=27Åb=24Å

a=48Åa=51Å

d=6Åd=3Å

Page 20: Using molecular replacement to  exploit multiple crystal forms

“Protein X”• 525 residues• Only distant homologues in PDB

• eight models with sequence identity about 20%

Page 21: Using molecular replacement to  exploit multiple crystal forms

Ensemble of 8 possible models

Page 22: Using molecular replacement to  exploit multiple crystal forms

Molecular replacement trials• MR with individual models failed

• complete or trimmed with FFAS server• MR with ensemble failed initially

• but now works with new “trim” option in phenix.ensembler

Page 23: Using molecular replacement to  exploit multiple crystal forms

Trimminguntrimmed

Page 24: Using molecular replacement to  exploit multiple crystal forms

Trimmingtrimmed

Page 25: Using molecular replacement to  exploit multiple crystal forms

Data sets• Space group P3112

Crystal

a=b c dmin ΔBaniso λ

Native 70.9Å 286.0Å 2.4Å 35Å2 0.9728Å

GdCl3 68.8Å 289.0Å 3.3Å 96Å2 1.475ÅNaI 72.5Å 286.4Å 3.2Å(3.

6Å)92Å2 0.9763

Å

Page 26: Using molecular replacement to  exploit multiple crystal forms

Experimental phasing with GdCl3• GdCl3 derivative diffracts to about 3.3Å

• good anomalous signal (phenix.xtriage) to 4.3Å

• solve substructure with phenix.hyss (4 sites)• phase with Phaser• solvent flattening• see some features of fold, not complete trace

Page 27: Using molecular replacement to  exploit multiple crystal forms

Real-space MR against GdCl3 map• Use real-space MR to place models in

density• cut out density from SAD map

• back-transform, treat as observed data• rotation search, phased translation

• Resolution, phases too poor to rebuild• Model provides starting mask

Page 28: Using molecular replacement to  exploit multiple crystal forms

Real-space MR model in Gd density

Page 29: Using molecular replacement to  exploit multiple crystal forms

Solve native crystal with GdCl3 density• Use real-space MR model to construct

envelope• Cut out GdCl3 density for one molecule

• place in large unit cell (4x extent in each direction)

• FFT to get molecular transform• Use density for MR solution of native crystal

• RFZ=3.8, TFZ=22.9• or just rigid-body refinement starting from

identity operator

Page 30: Using molecular replacement to  exploit multiple crystal forms

Solve and phase iodide soak• Diffracts to 3.2Å, but data sparse beyond

3.6Å• good anomalous signal only to 5.4Å

(phenix.xtriage)• Ab initio substructure determination failed

• phenix.hyss• Rigid-body refinement of GdCl3 density model• Use Fc from MR solution as partial model for

MR-SAD phasing• SAD log-likelihood-gradient maps yield 11 sites

Page 31: Using molecular replacement to  exploit multiple crystal forms

Multi-crystal averaging• Get operators from transformations

applied to GdCl3 density• Starting maps from SAD phasing

(derivatives) or MR with GdCl3 density (native)

• Carried out with phenix.multi_crystal_average

Page 32: Using molecular replacement to  exploit multiple crystal forms

Morphing• Use phenix.morph_model to morph real-

space MR model into native averaged density• correlation increases from 0.296 to 0.338

Page 33: Using molecular replacement to  exploit multiple crystal forms

Initial model-building• Build with phenix.autobuild into averaged

native map, start from morphed MR model• 364 residues, 177 assigned to sequence• R=0.42, Rfree=0.48

Page 34: Using molecular replacement to  exploit multiple crystal forms

Iterative averaging and rebuilding• Carry on with iterative improvement

• MR-SAD phasing with current model• multi-crystal averaging• AutoBuild, do some manual rebuilding• MR-SAD phasing with updated model• multi-crystal averaging

• Iteration has improved anomalous substructures• GdCl3: 4 sites to 8 sites (2 split)• NaI: 11 sites to 14 sites

Page 35: Using molecular replacement to  exploit multiple crystal forms

Map after iterative process

Currentmodel

MR model

Page 36: Using molecular replacement to  exploit multiple crystal forms

Tools• Cutting out density

• phenix.cut_out_density (Tom Terwilliger)• cmapcut (Kevin Cowtan)

• Molecular replacement with density• Molrep• Phaser

• SAD phasing starting from density• Phaser SAD LLG, giving density as partial model

• Multi-crystal averaging• dmmulti• phenix.multi_crystal_average

Page 37: Using molecular replacement to  exploit multiple crystal forms

Acknowledgements• Phaser:

• Airlie McCoy, Gabor Bunkoczi• Angiotensinogen:

• Penny Stein, Robin Carrell, Aiwu Zhou• Mike Murphy, Fiona Broughton Pipkin

• “Protein X”• Mykhaylo Demydchuk, Aiwu Zhou,

Janet Deane, Penny Stein

Page 38: Using molecular replacement to  exploit multiple crystal forms

Randy Read, Airlie Randy Read, Airlie McCoy, Gabor Bunkoczi, McCoy, Gabor Bunkoczi,

Rob OeffnerRob Oeffner

Tom Terwilliger, Tom Terwilliger, Li-Wei HungLi-Wei Hung

The PHENIX Project

An NIH/NIGMS funded Program Project

Paul Adams, Ralf Grosse-Paul Adams, Ralf Grosse-Kunstleve, Pavel Afonine, Nat Kunstleve, Pavel Afonine, Nat

Echols, Nigel Moriarty, Jeff Echols, Nigel Moriarty, Jeff Headd, Nicholas Sauter, Peter Headd, Nicholas Sauter, Peter

ZwartZwart

Lawrence Berkeley Laboratory

Los Alamos National Laboratory

Jane & David Richardson, Jane & David Richardson, Vincent Chen, Chris Vincent Chen, Chris

Williams, Bryan Arendall, Williams, Bryan Arendall, Swati Jain, Bradley HintzeSwati Jain, Bradley Hintze

Cambridge University

Duke University